Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 437

2.

Biomarkers of Tuberculosis Severity and Treatment Effect: A Directed Screen of 70 Host Markers in a Randomized Clinical Trial.

Sigal GB, Segal MR, Mathew A, Jarlsberg L, Wang M, Barbero S, Small N, Haynesworth K, Davis JL, Weiner M, Whitworth WC, Jacobs J, Schorey J, Lewinsohn DM, Nahid P.

EBioMedicine. 2017 Nov;25:112-121. doi: 10.1016/j.ebiom.2017.10.018. Epub 2017 Oct 24.

3.

Association of UGT2B7 polymorphisms with risk of induced liver injury by anti-tuberculosis drugs in Chinese Han.

Chen G, Wu SQ, Feng M, Wang Y, Wu JC, Ji GY, Zhang MM, Liu QQ, He JQ.

Int J Immunopathol Pharmacol. 2017 Dec;30(4):434-438. doi: 10.1177/0394632017733638. Epub 2017 Sep 22.

4.

Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary Tuberculosis.

Aarnoutse RE, Kibiki GS, Reither K, Semvua HH, Haraka F, Mtabho CM, Mpagama SG, van den Boogaard J, Sumari-de Boer IM, Magis-Escurra C, Wattenberg M, Logger JGM, Te Brake LHM, Hoelscher M, Gillespie SH, Colbers A, Phillips PPJ, Plemper van Balen G, Boeree MJ; PanACEA Consortium.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01054-17. doi: 10.1128/AAC.01054-17. Print 2017 Nov.

5.

Effects on the QT Interval of a Gatifloxacin-Containing Regimen versus Standard Treatment of Pulmonary Tuberculosis.

Olliaro PL, Merle C, Mthiyane T, Bah B, Kassa F, Amukoye E, N Diaye A, Perronne C, Lienhardt C, McIlleron H, Fielding K.

Antimicrob Agents Chemother. 2017 Jun 27;61(7). pii: e01834-16. doi: 10.1128/AAC.01834-16. Print 2017 Jul.

6.

Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: study protocol for a prospective, multicenter, randomized, open-label, phase II trial.

Lee JY, Kim DK, Lee JK, Yoon HI, Jeong I, Heo E, Park YS, Lee JH, Park SS, Lee SM, Lee CH, Lee J, Choi SM, Park JS, Joh JS, Cho YJ, Lee YJ, Kim SJ, Hwang YR, Kim H, Ki J, Choi H, Han J, Ahn H, Hahn S, Yim JJ.

Trials. 2017 Feb 13;18(1):68. doi: 10.1186/s13063-017-1811-0.

7.

High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.

Boeree MJ, Heinrich N, Aarnoutse R, Diacon AH, Dawson R, Rehal S, Kibiki GS, Churchyard G, Sanne I, Ntinginya NE, Minja LT, Hunt RD, Charalambous S, Hanekom M, Semvua HH, Mpagama SG, Manyama C, Mtafya B, Reither K, Wallis RS, Venter A, Narunsky K, Mekota A, Henne S, Colbers A, van Balen GP, Gillespie SH, Phillips PPJ, Hoelscher M; PanACEA consortium.

Lancet Infect Dis. 2017 Jan;17(1):39-49. doi: 10.1016/S1473-3099(16)30274-2. Epub 2016 Oct 26.

8.

Pharmacokinetics of the First-Line Antituberculosis Drugs in Ghanaian Children with Tuberculosis with or without HIV Coinfection.

Antwi S, Yang H, Enimil A, Sarfo AM, Gillani FS, Ansong D, Dompreh A, Orstin A, Opoku T, Bosomtwe D, Wiesner L, Norman J, Peloquin CA, Kwara A.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e01701-16. doi: 10.1128/AAC.01701-16. Print 2017 Feb.

9.

Early Bactericidal Activity of AZD5847 in Patients with Pulmonary Tuberculosis.

Furin JJ, Du Bois J, van Brakel E, Chheng P, Venter A, Peloquin CA, Alsultan A, Thiel BA, Debanne SM, Boom WH, Diacon AH, Johnson JL.

Antimicrob Agents Chemother. 2016 Oct 21;60(11):6591-6599. doi: 10.1128/AAC.01163-16. Print 2016 Nov.

10.

Peak Plasma Concentration of Azithromycin and Treatment Responses in Mycobacterium avium Complex Lung Disease.

Jeong BH, Jeon K, Park HY, Moon SM, Kim SY, Lee SY, Shin SJ, Daley CL, Koh WJ.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):6076-83. doi: 10.1128/AAC.00770-16. Print 2016 Oct.

11.

Delamanid Coadministered with Antiretroviral Drugs or Antituberculosis Drugs Shows No Clinically Relevant Drug-Drug Interactions in Healthy Subjects.

Mallikaarjun S, Wells C, Petersen C, Paccaly A, Shoaf SE, Patil S, Geiter L.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):5976-85. doi: 10.1128/AAC.00509-16. Print 2016 Oct.

12.

Efficacy and Safety of 'Fixed Dose' versus 'Loose' Drug Regimens for Treatment of Pulmonary Tuberculosis in Two High TB-Burden African Countries: A Randomized Controlled Trial.

Aseffa A, Chukwu JN, Vahedi M, Aguwa EN, Bedru A, Mebrahtu T, Ezechi OC, Yimer G, Yamuah LK, Medhin G, Connolly C, Rida W, Aderaye G, Zumla AI, Onyebujoh PC; 4FDC Study Group.

PLoS One. 2016 Jun 20;11(6):e0157434. doi: 10.1371/journal.pone.0157434. eCollection 2016.

13.

A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis.

Conde MB, Mello FC, Duarte RS, Cavalcante SC, Rolla V, Dalcolmo M, Loredo C, Durovni B, Armstrong DT, Efron A, Barnes GL, Marzinke MA, Savic RM, Dooley KE, Cohn S, Moulton LH, Chaisson RE, Dorman SE.

PLoS One. 2016 May 9;11(5):e0154778. doi: 10.1371/journal.pone.0154778. eCollection 2016.

14.

Safety and efficacy of additional levofloxacin in tuberculous meningitis: A randomized controlled pilot study.

Kalita J, Bhoi SK, Betai S, Misra UK.

Tuberculosis (Edinb). 2016 May;98:1-6. doi: 10.1016/j.tube.2016.01.004. Epub 2016 Feb 3.

PMID:
27156611
15.

A randomised Phase II trial to evaluate the toxicity of high-dose rifampicin to treat pulmonary tuberculosis.

Jindani A, Borgulya G, de PatiƱo IW, Gonzales T, de Fernandes RA, Shrestha B, Atwine D, Bonnet M, Burgos M, Dubash F, Patel N, Checkley AM, Harrison TS, Mitchison D; International Consortium for Trials of Chemotherapeutic Agents in Tuberculosis, St George's University of London.

Int J Tuberc Lung Dis. 2016 Jun;20(6):832-8. doi: 10.5588/ijtld.15.0577.

PMID:
27155189
16.

Tackling the unknowns of short-course rifapentine-based treatment for active tuberculosis: a decision analysis.

Holland DP, Hamilton CD, Stout JE.

Int J Tuberc Lung Dis. 2016 Jun;20(6):827-31. doi: 10.5588/ijtld.15.0006.

PMID:
27155188
17.

Diagnostic patch testing following tuberculosis-associated cutaneous adverse drug reactions induces systemic reactions in HIV-infected persons.

Lehloenya RJ, Todd G, Wallace J, Ngwanya MR, Muloiwa R, Dheda K.

Br J Dermatol. 2016 Jul;175(1):150-6. doi: 10.1111/bjd.14492. Epub 2016 May 26.

PMID:
26918554
18.

The Association of Mycobacterium avium subsp. paratuberculosis with Inflammatory Bowel Disease.

Timms VJ, Daskalopoulos G, Mitchell HM, Neilan BA.

PLoS One. 2016 Feb 5;11(2):e0148731. doi: 10.1371/journal.pone.0148731. eCollection 2016.

19.

Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines.

Bekker A, Schaaf HS, Draper HR, van der Laan L, Murray S, Wiesner L, Donald PR, McIlleron HM, Hesseling AC.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2171-9. doi: 10.1128/AAC.02600-15. Print 2016 Apr.

20.

Impact of food on the pharmacokinetics of first-line anti-TB drugs in treatment-naive TB patients: a randomized cross-over trial.

Saktiawati AM, Sturkenboom MG, Stienstra Y, Subronto YW, Sumardi, Kosterink JG, van der Werf TS, Alffenaar JW.

J Antimicrob Chemother. 2016 Mar;71(3):703-10. doi: 10.1093/jac/dkv394. Epub 2015 Dec 11.

PMID:
26661397

Supplemental Content

Loading ...
Support Center